Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.
GLOBETECH PUBLISHING LLC

Spinal Fluid Biomarkers Predict Cognitive Decline in Individuals with Familial Risk of Alzheimer's Disease

By Labmedica International staff writers
Posted on 31 Oct 2013
Determination of two biomarkers in cerebrospinal fluid (CSF) allows prediction of development of cognitive impairment up to five years before appearance of symptoms in normal patients with familial risk of Alzheimer's disease.

Investigators at Johns Hopkins University (Baltimore, MD, USA) measured beta-amyloid 1–42 (Abeta1–42), total tau (t-tau), and phosphorylated tau (p-tau) proteins in CSF collected for the Biomarkers for Older Controls at Risk for Dementia (BIOCARD) project between 1995 and 2005, from 265 middle-aged healthy volunteers. Approximately three-quarters of this group had a close family member with Alzheimer’s disease, an indication of higher than normal risk of developing the disorder. Biochemical measurements and assessment of cognitive ability were repeated at yearly intervals.

Results revealed that the mean time from baseline to onset of mild cognitive symptoms was 5.41 years. This decline in cognitive ability was paralleled by increase in the levels of phosphorylated tau and beta amyloid found in CSF. The rate of change over time in the ratio of phosphorylated tau protein to beta amyloid was also predictive, with elevated p-tau indicating increased likelihood of development of cognitive symptoms.

“We wondered if we could measure something in the cerebral spinal fluid when people are cognitively normal to give us some idea of when they will develop difficulty,” said contributing author Dr. Marilyn Albert, professor of neurology at Johns Hopkins University. “The answer is yes.”

“When we see patients with high blood pressure and high cholesterol, we do not say we will wait to treat you until you get congestive heart failure. Early treatments keep heart disease patients from getting worse, and it is possible the same may be true for those with presymptomatic Alzheimer’s. But it has been hard to see Alzheimer’s disease coming, even though we believe it begins developing in the brain a decade or more before the onset of symptoms.”

The investigators pointed out that the biomarker ratio at this point was not accurate enough to predict precisely whether a particular individual is progressing to dementia, and further analysis of information about the group over time is needed.

The study was published in the October 16, 2013, online edition of the journal Neurology.

Related Links:
Johns Hopkins University


KARL HECHT GMBH & CO KG
MEDLAB Asia
CELLAVISION AB

Channels

Microbiology

view channel
Image: The Xpert MTB/RIF cartridge-based, fully automated molecular diagnostic test for tuberculosis (Photo courtesy of Cepheid).

Test Helps Physicians Remove Suspected TB Patients from Isolation

Tuberculosis (TB) is caused by the Mycobacterium tuberculosis complex (MTB-complex) and usually attacks the lungs and many people carry the MTB-complex bacteria without ever developing active disease.... Read more

Lab Tech.

view channel
Image:  The Flame – a miniature spectrometer for medical diagnostics, biotechnology, and life sciences, that brings flexible optical sensing power to laboratory and point-of-care instrument integration (Photo courtesy of Ocean Optics).

Next Generation Miniature Spectrometer Brings Flexibility to Diagnostics and Biotechnology

The mini spectrometer combines decades of pioneering miniature spectrometer design expertise with leading techniques, adding flexible optical sensing power to laboratory and point-of-care instrument integration.... Read more

Industry News

view channel
Image: Under a new partnership for liquid handling measurement automation, Artel will provide STRATEC’s innovative “Tholos” technology, which measures liquid and solid contents of 96- and 384-well microplates, under the name Artel “SDS” - Sample Detection System (Photo courtesy of Artel).

Artel Expands Portfolio with STRATEC Partnership for Automation Technology

Artel (Westbrook, Maine, USA), a leader in laboratory liquid handling measurement systems, and STRATEC Biomedical AG (Birkenfeld, Germany), a leader in automated systems for clinical diagnostics and biotechnology,... Read more
 

Events

05 Mar 2015 - 08 Mar 2015
08 Mar 2015 - 12 Mar 2015
18 Mar 2015 - 20 Mar 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.